Back to top
more

Integer Holdings (ITGR)

(Delayed Data from NYSE)

$106.52 USD

106.52
379,870

-1.99 (-1.83%)

Updated Aug 1, 2025 03:59 PM ET

After-Market: $106.51 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Inogen's Solid Europe Business Shapes Q2, Prospects Bright

by Zacks Equity Research

Inogen's (INGN) Europe performance solid in Q2; guidance for 2018 encourages.

    Zacks Equity Research

    Surmodics' (SRDX) IVD Unit Boosts Growth, R&D Focus Solid

    by Zacks Equity Research

    Surmodics' (SRDX) strong focus on R&D to provide it a competitive edge in the MedTech space.

      Zacks Equity Research

      Boston Scientific to Expand Within PI Via VENITI Buyout

      by Zacks Equity Research

      Presence of venous obstructive disease visibly grows across the globe, indicating huge prospects for Boston Scientific (BSX) in the treatment market.

        Zacks Equity Research

        Here's Why You Should Dump DENTSPLY (XRAY) Stock Right Now

        by Zacks Equity Research

        DENTSPLY (XRAY) incurs goodwill and intangible impairment charge. A lowered guidance is a concern.

          Zacks Equity Research

          Zacks.com highlights: Turtle Beach, Integer Holdings and PCM

          by Zacks Equity Research

          Zacks.com highlights: Turtle Beach, Integer Holdings and PCM

            Zacks Equity Research

            Here's Why You Should Hold on to Ecolab (ECL) Stock Now

            by Zacks Equity Research

            Ecolab (ECL) is likely to gain from a robust product portfolio, new product launches and expanding customer base.

              Zacks Equity Research

              Varian Acquires humediQ, Boosts Motion Management Portfolio

              by Zacks Equity Research

              Varian (VAR) incorporates humediQ's coveted IDENTIFY technology in its comprehensive suite of oncology solutions.

                Zacks Equity Research

                Allscripts Sunrise Picked by UK's Maidstone and Tunbridge Wells

                by Zacks Equity Research

                Allscripts' (MDRX) Sunrise platform witnesses a suite of developments, fortifying the company's global foothold.

                  Zacks Equity Research

                  OPKO Health (OPK) Earnings & Revenues Beat Estimates in Q2

                  by Zacks Equity Research

                  OPKO Health (OPK) gains from robust demand for its flagship RAYALDEE; declining segmental revenues raise concern.

                    Zacks Equity Research

                    Buy 3 Stocks With Rising Cash Flows to Scoop Up Big Gains

                    by Zacks Equity Research

                    Even though profit is a company's goal, cash is its lifeblood for existence and a measure of resiliency.

                      Zacks Equity Research

                      Allscripts Gains From Strong Results in Q2, Competition Rife

                      by Zacks Equity Research

                      Allscripts (MDRX) continues to gain from solid Q2 results and EHR developments; a competitive industry is a concern.

                        Zacks Equity Research

                        Inogen (INGN) Beats on Q2 Earnings, Lifts '18 Sales Guidance

                        by Zacks Equity Research

                        Inogen (INGN) puts up solid segmental show in Q2; international sales surge.

                          Zacks Equity Research

                          Zacks.com highlights: Turtle Beach, PetroChina, Harsco, Integer Holdings and Triton International

                          by Zacks Equity Research

                          Zacks.com highlights: Turtle Beach, PetroChina, Harsco, Integer Holdings and Triton International

                            Zacks Equity Research

                            5 Top Stocks With Striking Net Profit Margin

                            by Zacks Equity Research

                            Five stocks with handsome net profit margin that investors can count on for stellar returns.

                              Zacks Equity Research

                              Integer Holdings (ITGR) Beats on Q2 Earnings, '18 View Solid

                              by Zacks Equity Research

                              Integer Holdings (ITGR) gains on solid Cardio & Vascular revenues and high organic sales; a solid guidance raises optimism.

                                Zacks Equity Research

                                Hill-Rom (HRC) Q3 Earnings Top Estimates, Margins Expand

                                by Zacks Equity Research

                                Hill-Rom (HRC) registers a solid year-over-year revenue rise on strong domestic growth, driven by a robust performance at Patient Support Systems and Surgical Solutions.

                                  Zacks Equity Research

                                  ITGR vs. ABMD: Which Stock Is the Better Value Option?

                                  by Zacks Equity Research

                                  ITGR vs. ABMD: Which Stock Is the Better Value Option?

                                    Zacks Equity Research

                                    Zimmer Biomet (ZBH) Q2 Earnings Top Estimates, Margins Drop

                                    by Zacks Equity Research

                                    The improvement within Zimmer Biomet's (ZBH) global Knee and Hip sales performance and ongoing growth within the Asia Pacific region are encouraging.

                                      Zacks Equity Research

                                      GNC Holdings (GNC) Q2 Earnings Beat, Revenues Miss Mark

                                      by Zacks Equity Research

                                      Though GNC Holdings' (GNC) domestic retail comps are slightly weaker than expected, the company performs strongly in e-commerce business and at International segment.

                                        Zacks Equity Research

                                        Baxter (BAX) Q2 Earnings Beat Estimates, Revenues Rise Y/Y

                                        by Zacks Equity Research

                                        Baxter (BAX) gains on the back of its core Renal Care segment in Q2; solid international sales encourage.

                                          Zacks Equity Research

                                          Zacks.com highlights: Hitachi, Integer Holdings, Panasonic and SunCoke Energy

                                          by Zacks Equity Research

                                          Zacks.com highlights: Hitachi, Integer Holdings, Panasonic and SunCoke Energy

                                            Zacks Equity Research

                                            Align Technology (ALGN) Beats on Earnings and Revenues in Q2

                                            by Zacks Equity Research

                                            Align Technology (ALGN) gains on solid contributions from Clear Aligner as well as Scanner and Service segments in Q2.

                                              Zacks Equity Research

                                              Chemed (CHE) Beats on Q2 Earnings & Revenues, View Raised

                                              by Zacks Equity Research

                                              Chemed (CHE) rides on strong contributions from the Roto-Rooter and VITAS businesses in Q2.

                                                Zacks Equity Research

                                                Stryker (SYK) Beats on Q2 Earnings, International Sales Up

                                                by Zacks Equity Research

                                                Stryker (SYK) gains from solid segmental performance in Q2.

                                                  Zacks Equity Research

                                                  Medidata (MDSO) Q2 Earnings Beat, Revenues Miss Estimates

                                                  by Zacks Equity Research

                                                  Medidata (MDSO) gains from solid segmental performance in Q2; banks on strategic buyouts.